Loading
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Previous close
$4.29
−$0.19 · -4.24%
Pre-market
$4.35
+$0.06 · +1.40%
Oct 8, 4:56 AM ET
Regular session · ET · Market data may be delayed.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Day range
Current $4.29
52-week range
Current $4.29
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
87
Deep Value
Sentiment
54
Mixed
Risk
33
Moderate Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Day range
Current $4.29
52-week range
Current $4.29
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 14.08M USD | 6.17M USD | 18.14M USD | 39.02M USD | 10.99M USD |
| Cost of goods sold | 363K USD | — | — | — | — |
| Gross profit | 13.72M USD | 6.17M USD | 18.14M USD | 39.02M USD | 10.99M USD |
| Research and development | 25.24M USD | 54.04M USD | 73.7M USD | 84.41M USD | 65.5M USD |
| Selling, general, and administrative | 15.89M USD | 22.11M USD | 22.48M USD | 17.83M USD | 17.14M USD |
| Operating expenses | 40.77M USD | 82.49M USD | 96.24M USD | 104.48M USD | 84.51M USD |
| Interest income | 4.07M USD | 6.59M USD | 5.69M USD | 2.19M USD | 127K USD |
| Interest expense | 97K USD | 137K USD | 459K USD | 1.73M USD | 2.86M USD |
| Depreciation and amortization | 363K USD | 1.38M USD | 1.4M USD | 1.43M USD | 1.75M USD |
| Operating income | −27.05M USD | −76.32M USD | −78.1M USD | −65.46M USD | −73.52M USD |
| Net income | −33.5M USD | −69.92M USD | −72.85M USD | −69.46M USD | −76.25M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.50
98.14% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 4, 2010 | 1:5 | — | — |
Effective Nov 4, 2010
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI25.58M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM18.43M0.02%78.56B USD0.19%$277.7-1.29%
State Street SPDR S&P Biotech ETFXBI13.11M0.13%10.08B USD0.35%$150.23-0.44%
Vanguard Extended Market ETFVXF9.31M0.01%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO6.82M0.05%14.25B USD0.24%$355.37-1.43%
iShares Biotechnology ETFIBB5.41M0.05%10.4B USD0.44%$203.34+0.12%
Vanguard Russell 2000 ETFVTWO4.69M0.03%18B USD0.06%$112.21-1.26%
Janus Henderson Small Cap Growth Alpha ETFJSML4.04M1.12%360.59M USD0.30%$86.5304-1.55%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOJanus Henderson Small Cap Growth Alpha ETFJSMLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
